@article{fdi:010037887,
  title = {{C}orrelations between treatment outcome and both anti-{MSP}1(19) antibody response and erythrocyte-related genetic factors in {P}lasmodium falciparum malaria},
  author = {{A}ubouy, {A}gn{\`e}s and {M}igot {N}abias, {F}lorence and {D}eloron, {P}hilippe},
  editor = {},
  language = {{ENG}},
  abstract = {{T}reatment efficacy is related to the interaction of three parameters: drug, parasites, and human factors. {T}he role of human factors in treatment outcome has been poorly documented to date, although human genetic factors and specific immunity have been related to protection against malaria. {T}his study aimed to evaluate a possible cooperation between drug efficacy and host factors in treatment success. {T}he contribution of host factors to treatment efficacy was studied in {G}abonese children with a non-severe malaria attack. {C}hildren (n = 232) aged under 10 years were treated with either sulfadoxine-pyrimethamine or amodiaquine. {T}he influence of erythrocyte-related genetic factors and humoral immune responses ({I}g{G} and subclasses) against {MSPI}19 on anti-malarial treatment outcome during a 28-day follow-up was studied. {S}ickle-cell trait carriage and anti-{MSPI}19 {I}g{G}3 levels were related to lower parasite densities at enrolment (multiple linear regression analysis, {P} <= 0.005). {S}trikingly, early failures after {AQ} or {SP} treatment were associated with decreased anti-{MSPI}19 {I}g{G}, lg{G}1 and {I}g{G}3 levels at enrolment. {H}owever, this finding was achieved in a low number of children presenting with an early failure. {K}inetics of anti-{MSPI}19 {I}g{G} and subclasses between {D}ays 0 and 28 were also related to treatment efficacy, as the most effective treatment (sulfadoxine-pyrimethamine) was characterised by a higher elevation of antibody titres by {D}ay 28. {N}o effect of erythrocyte-related genetic factors on treatment outcome was shown, although the protective role of sickle-cell trait against higher parasitaemias was confirmed at enrolment. {O}ur data suggest that anti-{MSPI}19 {I}g{GI} may have a supportive role during the first days of treatment to prevent early failures. {T}he interference between drug efficacy, immunity and human genetic factors needs further investigation to be elucidated.},
  keywords = {{P}lasmodium falciparum ; treatment efficacy ; human genetic factors ; anti {MSP}119 {I}g{G}},
  booktitle = {},
  journal = {{I}nfection {G}enetics and {E}volution},
  volume = {7},
  numero = {2},
  pages = {147--154},
  ISSN = {1567-1348},
  year = {2007},
  DOI = {10.1016/j.meegid.2006.07.001},
  URL = {https://www.documentation.ird.fr/hor/fdi:010037887},
}